Actelion shares fall after haemorrhage drug fails to impress in experts’ study

first_img Show Comments ▼ Monday 27 September 2010 7:57 pm More From Our Partners Biden received funds from top Russia lobbyist before Nord Stream 2 giveawaynypost.comRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgPuffer fish snaps a selfie with lucky divernypost.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.org980-foot skyscraper sways in China, prompting panic and evacuationsnypost.comMark Eaton, former NBA All-Star, dead at 64nypost.comI blew off Adam Sandler 22 years ago — and it’s my biggest regretnypost.comSupermodel Anne Vyalitsyna claims income drop, pushes for child supportnypost.comKamala Harris keeps list of reporters who don’t ‘understand’ her: reportnypost.comKiller drone ‘hunted down a human target’ without being told tonypost.comSidney Crosby, Alex Ovechkin are graying and frayingnypost.comConnecticut man dies after crashing Harley into live bearnypost.comWhy people are finding dryer sheets in their whatsapp ACTELION’S experimental drug Clazosentan is unlikely to make it to market after it failed in a late-stage study, dealing the biotech group another blow following a setback for its key drug Tracleer.Shares in the Swiss group closed down almost eight per cent at SwFr 40 yesterday.“The failure of clazosentan is bad news for Actelion,” said Sarasin analyst David Kaegi.“The study was potentially the most important catalyst for Actelion shares this year. “According to my estimates, clazosentan had sales potential of up to SwFr1bn (£850m),” he said. Actelion, which is trying to cut its dependence on heart and lung treatment Tracleer, said clazosentan failed to meet its primary endpoint in the Conscious-2 trial in patients with aneurysmal subarachnoid haemorrhage, a type of bleeding in the brain.The failure in the long-awaited Phase III study means it is very unlikely that clazosentan will make it to market, although a company spokesman said all the data still needed to be evaluated and the group would provide an update with Actelion’s third-quarter results on 21 October. Another late-stage trial is still ongoing. “We have four drugs on the market and a growing revenue stream,” the spokesman said. whatsapp Sharecenter_img by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeMisterStoryWoman Files For Divorce After Seeing This Photo – Can You See Why?MisterStoryTotal PastThe Ingenious Reason There Are No Mosquitoes At Disney WorldTotal PastNoteabley25 Funny Notes Written By StrangersNoteableyMoneyPailShe Was A Star, Now She Works In ScottsdaleMoneyPailSerendipity TimesInside Coco Chanel’s Eerily Abandoned Mansion Frozen In TimeSerendipity TimesBrake For ItThe Most Worthless Cars Ever MadeBrake For ItBetterBe20 Stunning Female AthletesBetterBemoneycougar.comThis Proves The Osmonds Weren’t So Innocentmoneycougar.comautooverload.comDeclassified Vietnam War Photos The Public Wasn’t Meant To Actelion shares fall after haemorrhage drug fails to impress in experts’ study Tags: NULL KCS-content last_img

Leave a Reply

Your email address will not be published. Required fields are marked *